AOBiome’s B244 Eases Eczema Symptoms, Helps Tame Itch

OBiome's B244 platform is a patented, proprietary, topical formulation of ammonia oxidizing bacteria.

AOBiome Therapeutics, Inc.’s B244 treatment demonstrated significant improvements in eczema severity and itch reduction 

The Phase 2b clinical data is published in Lancet's eClinicalMedicine.

In the trial, 547 patients were assigned to a high-dose, low-dose, or placebo group. The trial was run across more than 50 clinical sites in the US, in collaboration with Biorasi, LLC, a clinical research organization.

After 4 weeks of use, the following key results were obtained:

• Itch was reduced by 34% compared to placebo, as measured by the Worst Itch Numeric Rating Score (WI-NRS) and achieved a clinically meaningful itch response (30.8% B244 vs 21.8% Placebo in ≥4-point improvement in WI-NRS from baseline).
• Eczema severity improvements were also seen, with 29.3% and 27.7% of patients in the high and low dose groups of B244 achieving EASI-75 success vs. 15.8% in the placebo group and with 26.2% and 21.7% of patients in the high and low dose groups of B244 achieving IGA success (≥2-point improvement in IGA to clear or almost clear) vs. 12.3% in the placebo group.
• B244 was well-tolerated, with no serious adverse events. Treatment-emergent adverse events (TEAE) and treatment-related TEAEs were infrequent, mild, and transient.

"B244 is a promising new non-steroidal therapy for AD, with a very novel mechanism of action. The study was well designed, and the results are very promising. B244 may address a number of unmet needs for atopic dermatitis patients," says Dr. Jonathan Silverberg, Director of Clinical Research at the George Washington University School of Medicine and Health Sciences, in a news release. 

According to Todd Krueger, President and CEO of AOBiome Therapeutics, Inc., "This publication represents the recognition of B244's efficacy and differentiation in addressing this population. The fact it has so few side effects reinforces the commercial opportunity to become first line therapy before patients escalate to more expensive, risky, or invasive therapies."

About B244

AOBiome's B244 platform is a patented, proprietary, topical formulation of ammonia oxidizing bacteria. Once deployed, B244 produces nitric oxide, a signaling molecule known to regulate inflammation and vasodilation. B244 has been observed to be safe and well-tolerated in clinical studies to date.

Additionally, recently published immunology data demonstrates that B244 can reduce the inflammatory and pruritic cytokines IL-4, IL-5, and IL-13. See full article at: https://www.nature.com/articles/s41598-021-93299-1.